Topic: Metabolic Bone Disease: From Basic Science to Clinical Frontier

Metabolic bone disease is defined as a diverse group of disorders that result in abnormalities of (if) bone mass, (ii) structure mineral homeostasis, (iii) bone turnover, or (iv) growth. The most prevalent form is osteoporosis, characterized by microstructural deterioration of bone tissue and decreased bone mineral density. 55% of the subjects aged ≥50 years worldwide suffer from osteopenia or osteoporosis. The link between the lifetime risk of fracture of the hip, wrist, or vertebral regions and osteoporosis has already been identified. Beyond compromising athletic ability, osteoporotic fractures severely impact daily functionality and mobility, resulting in personal and societal burdens. 

In recent decades, significant progress has been made in pharmaceuticals and treatments for metabolic bone disease,  particularly in bone homeostasis and bone remodeling. However, a substantial knowledge gap remains between the clinical demands and basic research in this field. Translational research, known as “bench-to-bedside” research, holds great potential for bridging this gap. The objective of this Research Topic is to highlight translational studies focused on novel drugs and therapeutic substances for the prevention and treatment of metabolic bone disease, with an emphasis on bone remodeling. The articles in this collection will contribute to a deeper understanding of the mechanisms that underly metabolic bone disease. Furthermore, we aim to explore advanced technologies in drug delivery, targeting methods, release kinetics and distributions within the bone metabolism system.

This Research Topic will primarily focus on metabolic bone disease, spanning from basic science to the clinical frontier. We invite Original Research and Review articles focusing on, but not limited to, the preclinical assessments of novel therapeutic or preventive treatments for metabolic bone disease, and mechanistic studies that enhance our understanding of the disease. Additionally, we welcome evidence-based clinical studies on plant-based natural products and phytochemicals for the treatment of metabolic bone disease.